Ms. Reeve is an accomplished biopharmaceutical executive with more than 25 years of global financial experience across pharmaceutical, medical device, and bio-pharma companies. Most recently, Ms. Reeve served as Chief Financial Officer of Constellation Pharmaceuticals, Inc., a development-stage oncology company, prior to its acquisition by MorphoSys AG in 2021. Ms. Reeve led Constellation’s initial public offering in 2018 and raised over $700m for the company during her tenure.

Prior to Constellation, Ms. Reeve acted as interim Chief Financial Officer and Corporate Controller of Parexel International, a global biopharmaceutical services company, where she was responsible for all aspects of finance, investor relations, procurement, and facilities, leading a team of over 950 people. In this role, she led the finance aspects of a sell-side process which culminated in an agreement to take the company private in a $5 billion leveraged buy-out.

Earlier in her career, Ms. Reeve served as Chief Financial Officer of both Inotek Pharmaceuticals and Aton Pharma. Additionally, she held senior finance and operational roles at Bristol Myers Squibb, Merck, and Novartis.

Ms. Reeve serves on the Board of Directors of Editas Medicine, Inc., Aadi Bioscience, Inc., and Ribon Therapeutics, Inc. She also serves on the Board of Trustees for Tufts Medical Center.